Grandfield & Dodd LLC Raises Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Grandfield & Dodd LLC boosted its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 1.8% during the third quarter, Holdings Channel.com reports. The fund owned 15,821 shares of the company’s stock after purchasing an additional 280 shares during the quarter. Grandfield & Dodd LLC’s holdings in Neurocrine Biosciences were worth $1,823,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Ashton Thomas Private Wealth LLC acquired a new position in shares of Neurocrine Biosciences in the 2nd quarter valued at about $28,000. Innealta Capital LLC purchased a new position in Neurocrine Biosciences in the second quarter valued at approximately $30,000. New Covenant Trust Company N.A. acquired a new position in Neurocrine Biosciences during the first quarter valued at approximately $32,000. EdgeRock Capital LLC purchased a new stake in Neurocrine Biosciences during the second quarter worth approximately $35,000. Finally, Plato Investment Management Ltd acquired a new stake in shares of Neurocrine Biosciences in the first quarter worth $41,000. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on NBIX shares. Barclays decreased their price target on shares of Neurocrine Biosciences from $180.00 to $160.00 and set an “overweight” rating for the company in a research report on Monday, September 9th. Raymond James reiterated an “outperform” rating and issued a $155.00 target price on shares of Neurocrine Biosciences in a research note on Thursday, October 10th. StockNews.com lowered Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, November 1st. Jefferies Financial Group upped their price target on Neurocrine Biosciences from $177.00 to $189.00 and gave the stock a “buy” rating in a report on Monday, August 19th. Finally, Needham & Company LLC restated a “hold” rating on shares of Neurocrine Biosciences in a research note on Monday, November 11th. Five research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $163.91.

Neurocrine Biosciences Trading Up 1.3 %

Shares of Neurocrine Biosciences stock opened at $119.13 on Wednesday. Neurocrine Biosciences, Inc. has a 1 year low of $108.14 and a 1 year high of $157.98. The company has a market cap of $12.06 billion, a P/E ratio of 31.94 and a beta of 0.35. The stock has a 50-day moving average price of $118.44 and a 200 day moving average price of $132.40.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.